Decibel Therapeutics CEO Steven Holtzman is really, officially retiring.

The departure of the longtime vet of Boston’s biotech scene — he was formerly an executive vice president at Biogen and CEO of the cancer-focused Infinity Pharmaceuticals — is part of a broader restructuring at Decibel. The company is also ditching some early discovery programs and narrowing its scientific focus to regenerating damaged cells and structures in the ear that cause hearing and balance disorders.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I am interested as a patient. I have idiopathic hearing loss in both ears caused by the death of the cells in my inner ears. I have tried to slow it by allergy shots and pomegranate juice drinks.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy